FRM
Fox Run Management’s Neurocrine Biosciences NBIX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-7,482
| Closed | -$828K | – | 1096 |
|
|
2025
Q1 | $828K | Buy |
+7,482
| New | +$828K | 0.13% | 268 |
|
|
2024
Q4 | – | Sell |
-6,824
| Closed | -$786K | – | 1069 |
|
|
2024
Q3 | $786K | Buy |
+6,824
| New | +$786K | 0.18% | 201 |
|
|
2024
Q2 | – | Sell |
-3,694
| Closed | -$509K | – | 969 |
|
|
2024
Q1 | $509K | Buy |
+3,694
| New | +$509K | 0.11% | 364 |
|
|
2022
Q3 | – | Sell |
-5,961
| Closed | -$581K | – | 756 |
|
|
2022
Q2 | $581K | Buy |
+5,961
| New | +$581K | 0.29% | 89 |
|
|
2022
Q1 | – | Sell |
-3,858
| Closed | -$329K | – | 633 |
|
|
2021
Q4 | $329K | Buy |
+3,858
| New | +$329K | 0.19% | 200 |
|
|
2021
Q3 | – | Sell |
-3,025
| Closed | -$294K | – | 571 |
|
|
2021
Q2 | $294K | Buy |
+3,025
| New | +$294K | 0.27% | 171 |
|
|
2020
Q4 | – | Sell |
-2,859
| Closed | -$275K | – | 251 |
|
|
2020
Q3 | $275K | Sell |
2,859
-79
| -3% | -$7.6K | 0.69% | 55 |
|
|
2020
Q2 | $358K | Buy |
+2,938
| New | +$358K | 0.47% | 69 |
|
|
2019
Q4 | – | Sell |
-3,111
| Closed | -$280K | – | 478 |
|
|
2019
Q3 | $280K | Sell |
3,111
-1,479
| -32% | -$133K | 0.25% | 179 |
|
|
2019
Q2 | $388K | Buy |
+4,590
| New | +$388K | 0.26% | 137 |
|
|
2019
Q1 | – | Sell |
-5,021
| Closed | -$359K | – | 618 |
|
|
2018
Q4 | $359K | Buy |
5,021
+3,120
| +164% | +$223K | 0.19% | 211 |
|
|
2018
Q3 | $234K | Buy |
+1,901
| New | +$234K | 0.1% | 432 |
|
|
2017
Q2 | – | Sell |
-8,300
| Closed | -$359K | – | 757 |
|
|
2017
Q1 | $359K | Sell |
8,300
-16,500
| -67% | -$714K | 0.15% | 302 |
|
|
2016
Q4 | $960K | Buy |
24,800
+20,500
| +477% | +$794K | 0.5% | 10 |
|
|
2016
Q3 | $218K | Buy |
+4,300
| New | +$218K | 0.13% | 373 |
|